

## Special Issue

# Novel Therapeutic Approaches in Neuroendocrine Tumors

### Message from the Guest Editor

Neuroendocrine tumors (NETs) are a heterogeneous class of neoplasms arising from the diffuse neuroendocrine system that may occur at many different anatomical sites. Management of NETs represents a clinical challenge because of their late onset and absence of selective biomarkers. High-grade tumors are often treated with cytotoxic chemotherapy, while low-grade tumors are usually treated with somatostatin analogs as well as radio-conjugated somatostatin analogs. Although these approaches have proven effective in slowing tumor growth their efficacy is limited to specific patient populations. This Special Issue aims to address recent advances in the development of new therapeutic strategies for the treatment of NETs.

---

### Guest Editor

Dr. Federica Campolo

Department of Experimental Medicine, "Sapienza" University of Rome,  
Viale Regina Elena 324, 00161 Rome, Italy

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/156821](https://mdpi.com/si/156821)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)